Evommune Announces Top Line Data from Phase 2 Trial of EVO756 in Chronic Inducible Urticaria Demonstrating Robust Activity and Favorable Safety Profile May 28, 2025
Evommune Initiates Phase 2b Trial of MRGPRX2 Antagonist, EVO756, in Adults with Moderate to Severe Chronic Spontaneous Urticaria April 15, 2025
Evommune Announces $115 Million Series C Financing to Accelerate Advancement of Clinical-Stage Pipeline Addressing Chronic Inflammatory Diseases November 4, 2024
